"Anti-cancer beneficial bacteria" unexpectedly appeared at the annual cancer conference! CBM588 combined with immunotherapy to extend lung cancer survival?
EGFR-TKI resistance may affect the success or failure of treatment for lung cancer patients
The 28th Taiwan Joint Cancer Academic Annual Conference will be held grandly at the Taipei Marriott Hotel on May 4, 2024. The annual meeting invites oncology experts and scholars from Taiwan and abroad to gather together to discuss the latest advances and future directions in cancer treatment. Among them, probiotics have attracted much attention in enhancing immunotherapy.
On the first day, Professor Shiu-Kee Ho of the Taiwan Genomics and Genetics Society delivered a keynote speech entitled “Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR-TKI failure”. The speech focused on how to develop effective immunotherapy strategies for patients with advanced non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations who have failed EGFR tyrosine kinase inhibitor (TKI) treatment.
Lung cancer is the leading cause of cancer death worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of the total number of lung cancers. In recent years, precision therapy represented by EGFR-TKI has brought new hope to patients with EGFR mutant NSCLC. However, despite impressive initial efficacy, most patients eventually experience disease progression due to drug resistance. How to overcome EGFR-TKI resistance and prolong patient survival has become an urgent clinical problem that needs to be solved.
“Anti-cancer beneficial bacteria” unexpectedly appeared at the annual cancer conference! CBM588 combined immunotherapy “5 major benefits”
In addition, foreign journal studies also pointed out the important role of the intestinal microbiome in tumor immunotherapy. Studies have found that healthy intestinal flora can enhance the efficacy of immune checkpoint inhibitors (ICIs), while bacterial imbalance may lead to drug resistance.
It is worth mentioning that Clostridium butyricum MIYAIRI 588 shows potential in adjuvant immunotherapy. The role of CBM588 in the field of tumor immunity is reflected in the following aspects:
Regulate the intestinal microbiome: It can optimize the structure of intestinal flora, promote the growth of beneficial bacteria, inhibit harmful bacteria, maintain the balance of intestinal microecology, and relieve digestive tract symptoms caused by treatment.
Enhance immune cell activity: It can stimulate the activation of immune cells such as dendritic cells, natural killer cells, and T lymphocytes, and enhance the host’s anti-tumor immune response.
Induce T cell differentiation: It can induce gamma-delta T cells, repair mucosal tissue, and enhance anti-tumor immunity.
Reduce immune-related adverse reactions: It can regulate the immune system, reduce autoimmune adverse reactions caused by ICI, and improve patients’ tolerance to immunotherapy.
Enhance the efficacy of ICI: combined with ICI, it can significantly improve the efficacy and prolong the survival of patients.
This joint cancer academic annual meeting provides an important platform for tumor immunotherapy research and clinical application, and promotes exchanges and cooperation between academia and industry. Experts attending the meeting called for strengthening basic research and clinical trials, promoting the integrated development of immunotherapy and precision medicine, and bringing hope of survival to more cancer patients. At the same time, the mechanism of action of probiotics such as uterine bacteria in tumor treatment should be studied in depth, and the combined strategy of probiotics and immunotherapy should be optimized to open up a new path for cancer treatment.
Extended reading:
